Stingray Therapeutics, Inc. — Form D

Stingray Therapeutics, Inc. of DALLAS, TX, a company, filed a Form D exempt-offering notice with the SEC on 2024-02-02. The offering totals $450K, of which $437K was reported sold. Industry: Biotechnology.

Offering

Filed: 2024-02-02
Form: D
Accession: 0001759143-24-000001
Industry: Biotechnology
Exemptions: 06b
Total offering: $450K
Amount sold: $437K
Remaining: $13K
Investors: 21
Date of first sale: 2023-12-19
Revenue range: Decline to Disclose
SEC file number: 021-504213

Issuer

Name: Stingray Therapeutics, Inc.
CIK: 0001759143
Entity type: Corporation
Jurisdiction: DELAWARE
Incorporated: 2018
Address: HEALTH WILDCATTERS INCUBATOR, DALLAS, TX, 75247
Phone: 317-517-9500

Officers, directors & promoters (11)

Name	Role	Location
Sunil P Sharma	Director	Dallas, TX
Sunil P Sharma	Executive Officer	Dallas, TX
Sunil P Sharma	Promoter	Dallas, TX
Uma P Bhatt	Director	Dallas, TX
Uma P Bhatt	Executive Officer	Dallas, TX
Scott Andrew Jordan	Director	Houston, TX
Scott Andrew Jordan	Executive Officer	Houston, TX
Scott Andrew Jordan	Promoter	Houston, TX
Jonathan P Northrup	Director	Gaithersburg, MD
Jonathan P Northrup	Executive Officer	Gaithersburg, MD
Jonathan P Northrup	Promoter	Gaithersburg, MD

Other filings by this issuer (6)

Filed	Form	Offering	Sold
2024-05-14	D	$5.0M	$25K
2023-12-28	D/A	$6.7M	$6.6M
2023-03-31	D	$5.2M	$3.9M
2021-05-26	D/A	$3.0M	$1.5M
2020-10-13	D/A	$1.5M	$117K
2020-08-13	D	$1.5M	$52K

More